Analysts Offer Predictions for ENTA FY2030 Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Research analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Enanta Pharmaceuticals in a report released on Tuesday, November 18th. HC Wainwright analyst B. Folkes forecasts that the biotechnology company will post earnings per share of ($2.27) for the year. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.65) per share.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, November 17th. The biotechnology company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.26. The company had revenue of $15.13 million during the quarter, compared to analyst estimates of $15.60 million. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%.

Several other equities analysts have also recently issued reports on the company. JPMorgan Chase & Co. assumed coverage on Enanta Pharmaceuticals in a research report on Friday, November 14th. They set an “overweight” rating and a $17.00 price target on the stock. Jefferies Financial Group raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the stock from $14.00 to $20.00 in a report on Wednesday, October 1st. JMP Securities increased their price target on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a “market outperform” rating in a report on Tuesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Westpark Capital raised their price objective on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, September 30th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $20.29.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ ENTA traded up $0.55 during midday trading on Thursday, hitting $12.68. 32,265 shares of the company’s stock were exchanged, compared to its average volume of 403,155. Enanta Pharmaceuticals has a twelve month low of $4.09 and a twelve month high of $15.34. The stock’s 50 day moving average price is $10.45 and its 200-day moving average price is $8.36. The firm has a market cap of $270.97 million, a P/E ratio of -2.91 and a beta of 0.88.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. boosted its holdings in shares of Enanta Pharmaceuticals by 5.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company’s stock valued at $720,000 after purchasing an additional 6,549 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Enanta Pharmaceuticals by 11,558.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 5,779 shares during the last quarter. CWM LLC lifted its stake in shares of Enanta Pharmaceuticals by 22.1% in the 2nd quarter. CWM LLC now owns 21,464 shares of the biotechnology company’s stock valued at $162,000 after acquiring an additional 3,879 shares during the last quarter. Ieq Capital LLC acquired a new position in Enanta Pharmaceuticals in the 1st quarter worth about $232,000. Finally, Nuveen LLC bought a new position in Enanta Pharmaceuticals in the first quarter valued at about $313,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.